Stockscreener 앱 받기
157.77
0.76%
1.19
시간 외 거래:
160.00
2.23
+1.41%
전일 마감가:
$156.58
열려 있는:
$156.75
하루 거래량:
2.23M
Relative Volume:
0.74
시가총액:
$33.54B
수익:
$742.00K
순이익/손실:
$-1.37B
주가수익비율:
-22.31
EPS:
-7.0731
순현금흐름:
$-1.07B
1주 성능:
+9.42%
1개월 성능:
+8.31%
6개월 성능:
+105.59%
1년 성능:
+303.09%
1일 변동 폭
$156.44
$161.63
1주일 범위
$143.47
$161.63
52주 변동 폭
$34.00
$166.50
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-02-27 | 재개 | UBS | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines (RVMD) Is Up 7.8% After Phase 3 Survival Data Validates RAS(ON) Strategy - simplywall.st
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS - GlobeNewswire Inc.
Revolution Medicines (NASDAQ: RVMD) insider sells 132,871 shares totaling $19.29M - Stock Titan
Revolution Medicines (NASDAQ: RVMD) affiliate reports sale of 2,958 shares under Rule 144 - Stock Titan
Revolution Medicines (NASDAQ: RVMD) insider sale of 2,753 shares for $273,869.54 - Stock Titan
Revolution Medicines (NASDAQ: RVMD) insider sales total 43,691 shares reported - Stock Titan
Stephen M. Kelsey (RVMD) files to sell 4,071 restricted shares; prior 4,302 sold - Stock Titan
Insider sale: Margaret Horn notifies sale of 14,583 RVMD shares (RVMD) - Stock Titan
RVMD: 90,000 shares registered for sale after option exercise (RVMD) - Stock Titan
[Form 4] Revolution Medicines, Inc. Insider Trading Activity - Stock Titan
Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy - Yahoo Finance
Revolution Medicines upgraded to buy after Dara... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Revolution Medicines: Strong Data, Big Market (Rating Upgrade) - Seeking Alpha
Revolution Medicines (RVMD) Stock After RASolute 302 Phase 3 Success A Fresh Look At Valuation - simplywall.st
Number of shareholders of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Bernstein initiates coverage of Revolution Medicines (RVMD) with market perform recommendation - MSN
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD - Yahoo Finance
RVMD: Insider files Form 144 to sell 10,000 shares (NASDAQ: RVMD) - Stock Titan
Can Revolution Medicines Be a Game-Changer Stock? - The Motley Fool
RVMD Maintained by Evercore ISI Group -- Price Target Raised to $220 - GuruFocus
Revolution Medicines Inc. Warrant (RVMDW) Edges Higher Amid Modest Trading ActivityFibonacci Entry Signals - newsline.com
Tango shares surge on early pancreatic cancer combination data - The Pharma Letter
UBS Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $175 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Tango Dances Toward Phase III With Positive Vopimetostat/Daraxonrasib Data - Citeline News & Insights
Revolution Medicines (RVMD) Reports Promising Data on Vopimetost - GuruFocus
Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment - Barron's
Biotech Surges 45% On Eye-Popping Pancreatic Cancer Test - Investor's Business Daily
Revolution Medicines (RVMD) Strengthens PDAC Position with New D - GuruFocus
‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response - BioSpace
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller? - Insider Monkey
Why Revolution Medicines (RVMD) Is Down 8.8% After Phase 3 Daraxonrasib Pancreatic Cancer Survival Data Release And What's Next - simplywall.st
J&J spends $1 billion to enter KRAS race for cancer treatments - statnews.com
Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate - statnews.com
Revolution Medicines, Inc. (RVMD) Stock Analysis: Unlocking a 24.86% Upside Amidst Biotech Breakthroughs - DirectorsTalk Interviews
Total equity of Revolution Medicines, Inc. – XETR:42Z - TradingView
Debt to assets ratio of Revolution Medicines, Inc. – XETR:42Z - TradingView
ETFs Investing in Revolution Medicines, Inc. Stocks - TradingView
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Earnings call transcript: Revolution Medicines Q1 2026 focuses on strong cash position - Investing.com
Revolution Medicines (RVMD) Drops 4% as Biotech Sector Faces Renewed PressureTrading Ideas - newsline.com
Revolution Medicines in the spotlight for earnings post-trial win By Investing.com - Investing.com Nigeria
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report? - Yahoo Finance
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec - Endpoints News
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
Revolution Medicines is up 97% this year: Here are the bull and bear cases for this soaring biotech stock - MSN
Revolution Medicines Stock Surges on Promising Cancer Drug Data - IndexBox
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. - The Motley Fool
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.47%
자본화:
|
볼륨(24시간):